Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Asparaginase + Dexamethasone + DT2216 + Vincristine Sulfate|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Asparaginase||Elspar||L-asparaginase|ASP-1||Elspar (asparaginase) is an enzyme that converts L-asparagine to L-aspartic acid and ammonia, reducing the available L-asparagine, which may result in cell-cycle arrest and apoptosis in leukemia cells (NCI Drug Dictionary).|
|DT2216||BCL-XL inhibitor 11||DT2216 is a small molecule proteolysis-targeted chimera (PROTAC) that binds to BCL-XL and targets it for degradation, potentially resulting in decreased tumor growth (PMID: 31792461).|
|Vincristine Sulfate||Oncovin||22-Oxovincaleukoblastine||Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||T-cell acute lymphoblastic leukemia||not applicable||Asparaginase + Dexamethasone + DT2216 + Vincristine Sulfate||Preclinical - Pdx||Actionable||In a preclinical study, the addition of DT2216 to therapy with Oncovin (vincristine), dexamethasone, and Elspar (asparaginase) resulted in increased survival in a chemotherapy-resistant patient-derived xenograft (PDX) model of T-cell acute lymphoblastic leukemia that expressed high levels of BCL2, MCL1, and BCL-XL (BCL2L1) (PMID: 31792461).||31792461|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|